Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain ...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

A senior Home Department official stated that 965 Bangladeshi nationals were arrested in 2022, followed by 1,014 in 2023; 947 in 2024; and ...

India's virtual digital asset sector is now high risk. Intelligence reports reveal extensive illegal activities including drug trafficking ...

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

Gurgaon Drug Racket: Authorities in Gurgaon have busted a major illegal pharmaceutical racket involving spurious Mounjaro KwikPen (tirzepat...

India faces a critical shortage of cancer specialists. A new rule for the PMJAY scheme now bars experienced oncologists without specific de...

The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...

India's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide...

Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufact...

Ethics Committee has also been allowed to add trial sites and investigators without the need to obtain a no objection certificate from the ...

Blame administrative lethargy, not judicial overreach, for regulatory vacuum, making India forgo a valuable economic activity, which raises...

Officials at the DCGI said the changes in the norms will ensure that consumers do not mistake the marketing firm to be the manufacturer of ...

Smruthi Organics today said it has received a notification from the USFDA highlighting violations of manufacturing norms at its Solapur pla...

A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla's first biosimilar drug Etanercept.

The government has deferred compulsory implementation of the new good manufacturing practices (GMP) norms for the drug industry by one year.